Altro Pharmaceuticals

Altro Pharmaceuticals, also known as Altrove Healthcare, is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological and ophthalmic conditions. Headquartered in Irvine, California, the company leverages a proprietary delivery platform to optimize the topical and ocular administration of therapeutic agents. Its lead candidate, ALT-101, is a topical phosphodiesterase 4 (PDE4) inhibitor that has completed Phase 2 clinical trials for the treatment of atopic dermatitis. The company's pipeline also includes ALT-201 for psoriasis and early-stage programs for glaucoma and diabetic retinopathy. Founded by experts in ophthalmology and clinical development, Altro Pharmaceuticals aims to provide safer and more effective treatment options for chronic inflammatory and vascular diseases of the skin and eye.